SLU-PP-332 100mg

Description

SLU-PP-332 100mg is the maximum documented research dose — representing the upper boundary of ERR agonism pharmacology as currently understood. At 100mg, this compound is producing the most comprehensive transcriptional reprogramming of metabolic tissue available in any single compound: complete ERRα/γ pathway saturation, maximal mitochondrial biogenesis drive, complete fast-to-slow fibre remodelling signalling, and the broadest suite of adaptive metabolic changes that exercise science research has identified as hallmarks of elite endurance adaptation. The systemic scope at this dose extends beyond skeletal muscle to cardiac muscle adaptation, adipose tissue lipolytic capacity, and hepatic metabolic function. This is the dose for researchers pushing the boundaries of what metabolic pharmacology can achieve. Individual response at this level is highly variable and rigorous monitoring is essential. Dose accuracy is absolutely non-negotiable — and it’s what Puralytix 99%+ verification provides. Every tablet precisely what it claims to be. Research at 100mg should operate within a formal monitoring framework. Systematic medical monitoring, baseline imaging where available, and detailed symptom tracking are advisable.